stockrow
Friday 6 November 2026
Export RNXT’s income statement to Excel — free account
RenovoRx, Inc.
RNXT Healthcare Biotechnology
RenovoRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 2,511.6% from fiscal 2024.
- Revenue
- +300.8%
- EPS
- 0.00%
- Free cash flow
- −12.7%
Quarter to September 2026, against a year earlier
1.14
0.05
−4.20%
Follow RNXT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
26.43 | 25.80 | 23.46 | 27.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.83) | (10.36) | (16.17) | (29.61) | |
P/B ratio |
5.47 | 3.41 | 5.16 | 8.10 | |
Price to Tangible BV |
5.47 | 3.41 | 5.16 | 8.10 | |
EV/Sales |
24.45 | 20.72 | 21.09 | 25.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.50) | (2.73) | (3.51) | (5.73) | |
EV/FCF |
(2.50) | (2.73) | (3.49) | (5.69) | |
Quick Ratio |
3.65 | 6.58 | 5.29 | 5.27 | |
Current Ratio |
4.02 | 7.15 | 5.74 | 5.65 | |
Net Debt/EBITDA |
1.99 | 3.56 | 2.83 | 3.22 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.14 | 0.10 | 0.16 | 0.23 | |
Operating CF/Net income |
1.03 | 1.05 | 0.98 | 0.70 | |
Capex/Depreciation |
0.00 | 0.00 | (14.20) | (3.80) | |
Research and Development Expense of Revenue |
636.97% | 218.12% | 132.01% | 116.42% | |
Selling, General and Administrative Expense of Revenue |
931.09% | 483.13% | 320.68% | 269.51% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
119.75% | 56.31% | 62.71% | 44.00% | |
Graham Net Nets |
0.18 | 0.29 | 0.18 | 0.12 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(38.10%) | (32.67%) | (31.63%) | (19.87%) | |
Free Cash Flow Yield |
(36.98%) | (29.43%) | (25.75%) | (16.26%) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.02 | |
Operating CF per Share |
(0.09) | (0.10) | (0.06) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.10) | (0.06) | (0.05) | |
Cash per Share |
0.20 | 0.33 | 0.20 | 0.22 | |
Shareholders Equity per Share |
0.15 | 0.30 | 0.19 | 0.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.15 | 0.30 | 0.19 | 0.19 | |
Free Cash Flow |
(3.02) | (3.71) | (2.94) | (2.56) | |
Working Capital |
5.93 | 11.80 | 8.93 | 9.72 | |
Capital Expenditures |
0.00 | — | (0.07) | (0.02) | |
Net Current Asset Value |
5.22 | 11.02 | 8.32 | 8.66 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.08 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.09 | 0.26 | 0.42 | 0.39 | |
Average Payables |
0.69 | 1.04 | 0.77 | 0.90 | |
Average Inventory |
— | — | — | 0.31 | |
Average Assets |
8.11 | 14.99 | 12.56 | 11.82 | |
Average Common Equity |
4.95 | 12.21 | 9.81 | 8.68 |
Columns are period end dates · fundamentals updated 5 Nov 2026